CSL Ltd

CSL

Company Profile

  • Business description

    CSL is one of the largest global biotech companies and has three main segments. CSL Behring either uses plasma-derived proteins or recombinants to treat conditions including immunodeficiencies, bleeding disorders, and neurological indications. CSL Seqirus is the world’s second-largest influenza vaccination business and was acquired in fiscal 2016. CSL Vifor is an iron deficiency and nephrology business and was acquired in fiscal 2023. CSL has a strong R&D track record, and the product portfolio and pipeline include nonplasma products as the firm continues to broaden its scope. Originally formed in Australia as a government-owned entity, CSL now earns roughly half its revenue in North America and a quarter in Europe.

  • Contact

    655 Elizabeth Street
    MelbourneVIC3000
    AUS

    T: +61 393891911

    E: [email protected]

    https://www.csl.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    30 June 2026

    Employees

    29,904

CSL Ltd News & Analysis

stocks

12 picks for an income portfolio - Q3 2025 update

Fifteen months in and passive income growth has exceeded my target.
investing

Podcast: Investing Compass

Morningstar Australia's podcast series.
stocks

Chart of the Week: Morningstar’s forecast for CSL’s future

We see gross margin expansion on efficiencies and limited tariff impact

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,299.0021.900.24%
CAC 407,919.6214.64-0.18%
DAX 4024,236.94150.99-0.62%
Dow JONES (US)46,270.46202.880.44%
FTSE 1009,452.779.900.10%
HKSE25,923.23481.881.89%
NASDAQ22,521.70172.91-0.76%
Nikkei 22547,685.84838.521.79%
NZX 50 Index13,307.4030.410.23%
S&P 5006,644.3110.41-0.16%
S&P/ASX 2008,990.9022.200.25%
SSE Composite Index3,904.7639.531.02%

Market Movers